Kinnate Biopharma Inc reports results for the quarter ended in June - Earnings Summary

Kinnate Biopharma

15/08/2022 12:59

* Kinnate Biopharma Inc  KNTE.OQ  reported a quarterly
adjusted
loss of 62 cents​​ per share for the quarter ended in June. The
mean expectation of eight analysts for the quarter was for a
loss of 64 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kinnate Biopharma Inc's reported EPS for the quarter was a
loss
of 62 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.5%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kinnate Biopharma Inc shares had risen by 25.0% this
quarter and
lost 11.1% so far this year.
    * The company reported a quarterly loss of $27.07 million.
    * Wall Street's median 12-month price target for Kinnate
Biopharma
Inc is $33.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 11:59 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.64          -0.62          Beat
 Mar. 31 2022      -0.61          -0.61          Met
 Dec. 31 2021      -0.59          -0.60          Missed
 Sep. 30 2021      -0.54          -0.57          Missed